{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:22:17Z","timestamp":1788434537444,"version":"build-2803163510"},"reference-count":28,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2017,8,29]],"date-time":"2017-08-29T00:00:00Z","timestamp":1503964800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2017,8,29]],"date-time":"2017-08-29T00:00:00Z","timestamp":1503964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Janssen Pharmaceutica NV"}],"content-domain":{"domain":["wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Clin Pract"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1111\/ijcp.12991","type":"journal-article","created":{"date-parts":[[2017,8,29]],"date-time":"2017-08-29T16:01:35Z","timestamp":1504022495000},"page":"e12991","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Tolerability of canagliflozin in patients with type 2 diabetes mellitus fasting during Ramadan: Results of the Canagliflozin in Ramadan Tolerance Observational Study (CRATOS)"],"prefix":"10.1155","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6598-6972","authenticated-orcid":false,"given":"Mohamed","family":"Hassanein","sequence":"first","affiliation":[{"name":"Endocrine Department; Dubai Hospital; Dubai Health Authority; Dubai United Arab Emirates"},{"name":"Cardiff University; Cardiff UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akram","family":"Echtay","sequence":"additional","affiliation":[{"name":"Division of Endocrinology; Lebanese University Medical School; Rafik Hariri University Hospital; Beirut Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Hassoun","sequence":"additional","affiliation":[{"name":"Dubai Diabetes Center; Dubai United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monira","family":"Alarouj","sequence":"additional","affiliation":[{"name":"Dasman Diabetes Institute; Kuwait City Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bachar","family":"Afandi","sequence":"additional","affiliation":[{"name":"Diabetes Center; Tawam Hospital; Al Ain United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffi","family":"Poladian","sequence":"additional","affiliation":[{"name":"Endocrinology; Mount Lebanon Hospital; Beirut Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Bennakhi","sequence":"additional","affiliation":[{"name":"Dasman Diabetes Institute; Kuwait City Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Nazar","sequence":"additional","affiliation":[{"name":"Janssen-Cilag Poland; Warsaw Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Bergmans","sequence":"additional","affiliation":[{"name":"Janssen-Cilag BV; Breda the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Keim","sequence":"additional","affiliation":[{"name":"Janssen-Cilag Portugal; Barcarena Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gill","family":"Hamilton","sequence":"additional","affiliation":[{"name":"Janssen UK; High Wycombe UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami T.","family":"Azar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine; American University of Beirut Medical Centre; Beirut Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,8,29]]},"reference":[{"key":"10.1111\/ijcp.12991-BIB0001|ijcp12991-cit-0001","unstructured":"International Diabetes Federation Diabetes and Ramadan: Practical Guidelines 2016 http:\/\/www.idf.org\/sites\/default\/files\/IDF-DAR-Practical-Guidelines-Final-Low.pdf"},{"key":"10.1111\/ijcp.12991-BIB0002|ijcp12991-cit-0002","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.2337\/diacare.27.10.2306","article-title":"A population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: results of the epidemiology of diabetes and Ramadan 1422\/2001 (EPIDIAR) study","volume":"27","author":"Salti","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1111\/ijcp.12991-BIB0003|ijcp12991-cit-0003","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/DMSO.S23261","article-title":"Pharmacological approaches to the management of type 2 diabetes in fasting adults during Ramadan","volume":"5","author":"Almaatouq","year":"2012","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1111\/ijcp.12991-BIB0004|ijcp12991-cit-0004","first-page":"628","article-title":"Switching from sulphonylurea to a sodium-glucose cotransporter2 inhibitor in the fasting month of Ramadan is associated with a reduction in hypoglycaemia","volume":"18","author":"Wan Seman","year":"2016","journal-title":"Diabetes\u00a0Obes Metab"},{"key":"10.1111\/ijcp.12991-BIB0005|ijcp12991-cit-0005","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/nyas.12852","article-title":"Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus","volume":"1358","author":"Rosenthal","year":"2015","journal-title":"Ann N Y Acad Sci"},{"key":"10.1111\/ijcp.12991-BIB0006|ijcp12991-cit-0006","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1463-1326.2012.01558.x","article-title":"Canagliflozin improves glycemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin","volume":"14","author":"Devineni","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1111\/ijcp.12991-BIB0007|ijcp12991-cit-0007","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.2337\/dc11-1926","article-title":"Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes","volume":"35","author":"Rosenstock","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1111\/ijcp.12991-BIB0008|ijcp12991-cit-0008","doi-asserted-by":"crossref","first-page":"e105638","DOI":"10.1371\/journal.pone.0105638","article-title":"Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes","volume":"9","author":"Sha","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1111\/ijcp.12991-BIB0009|ijcp12991-cit-0009","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/jcph.88","article-title":"Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus","volume":"53","author":"Devineni","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/ijcp.12991-BIB0010|ijcp12991-cit-0010","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/dom.12054","article-title":"Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise","volume":"15","author":"Stenl\u00f6f","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1111\/ijcp.12991-BIB0011|ijcp12991-cit-0011","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1007\/s00125-013-3039-1","article-title":"Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial","volume":"56","author":"Lavalle-Gonz\u00e1lez","year":"2013","journal-title":"Diabetologia"},{"key":"10.1111\/ijcp.12991-BIB0012|ijcp12991-cit-0012","first-page":"1267","article-title":"Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial","volume":"67","author":"Wilding","year":"2013","journal-title":"Int\u00a0J\u00a0Clin Pract"},{"key":"10.1111\/ijcp.12991-BIB0013|ijcp12991-cit-0013","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/dom.12273","article-title":"Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone","volume":"16","author":"Forst","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1111\/ijcp.12991-BIB0014|ijcp12991-cit-0014","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1185\/03007995.2013.850066","article-title":"Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study","volume":"30","author":"Stenl\u00f6f","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/ijcp.12991-BIB0015|ijcp12991-cit-0015","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","article-title":"Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial","volume":"382","author":"Cefalu","year":"2013","journal-title":"Lancet"},{"key":"10.1111\/ijcp.12991-BIB0016|ijcp12991-cit-0016","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3810\/hp.2013.04.1020","article-title":"Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial","volume":"41","author":"Bode","year":"2013","journal-title":"Hosp Pract"},{"key":"10.1111\/ijcp.12991-BIB0017|ijcp12991-cit-0017","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2337\/dc13-2762","article-title":"Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study","volume":"38","author":"Leiter","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1111\/ijcp.12991-BIB0018|ijcp12991-cit-0018","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/dom.12428","article-title":"Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes","volume":"17","author":"Bode","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1111\/ijcp.12991-BIB0019|ijcp12991-cit-0019","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.2337\/dc12-2491","article-title":"Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week, randomized trial","volume":"36","author":"Schernthaner","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1111\/ijcp.12991-BIB0020|ijcp12991-cit-0020","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/dom.12090","article-title":"Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease","volume":"15","author":"Yale","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1111\/ijcp.12991-BIB0021|ijcp12991-cit-0021","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/dom.12348","article-title":"Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease","volume":"16","author":"Yale","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1111\/ijcp.12991-BIB0022|ijcp12991-cit-0022","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2337\/dc14-1237","article-title":"Efficacy and safety of canagliflozin, an inhibitor of sodium glucose co-transporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes","volume":"38","author":"Neal","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1111\/ijcp.12991-BIB0023|ijcp12991-cit-0023","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/ijcp.12868","article-title":"Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates","volume":"70","author":"John","year":"2016","journal-title":"Int J Clin Pract"},{"key":"10.1111\/ijcp.12991-BIB0024|ijcp12991-cit-0024","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.2337\/dc12-2480","article-title":"Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society","volume":"36","author":"Seaquist","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1111\/ijcp.12991-BIB0025|ijcp12991-cit-0025","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/dc16-2215","article-title":"Glucose concentrations of less than 3.0 mmol\/L (54 mg\/dL) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"40","author":"International Hypoglycaemia Study Group","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1111\/ijcp.12991-BIB0026|ijcp12991-cit-0026","volume-title":"INVOKANA\u00ae (Canagliflozin) Tablets, for Oral Use [Package Insert]","year":"2016"},{"key":"10.1111\/ijcp.12991-BIB0027|ijcp12991-cit-0027","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3810\/pgm.2014.05.2753","article-title":"Safety and tolerability of canagliflozin in patients with type 2 diabetes: pooled analysis of phase 3 study results","volume":"126","author":"Usiskin","year":"2014","journal-title":"Postgrad Med"},{"key":"10.1111\/ijcp.12991-BIB0028|ijcp12991-cit-0028","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1080\/03007995.2016.1271780","article-title":"Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis","volume":"33","author":"Qiu","year":"2017","journal-title":"Curr Med Res Opin"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fijcp.12991","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ijcp.12991\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:10:15Z","timestamp":1643350215000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijcp.12991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,29]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"URL":"https:\/\/doi.org\/10.1111\/ijcp.12991","archive":["Portico"],"relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8,29]]}}}